ALXO•benzinga•
ALX Oncology Announces Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma. Combination Generated Complete Responses In 83% Of Patients With Indolent Relapsed
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 25, 2025 by benzinga